Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
about
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and LymphomagenesisAn essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation.Genetic landscape and deregulated pathways in B-cell lymphoid malignancies.The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomasCombination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers.BCL6 as a therapeutic target for lymphoma.3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro.AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.Transcribing malignancy: transcription-associated genomic instability in cancer.Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with / and / gene arrangements and potential molecular targeted therapies
P2860
Q28771717-BB0D56E1-A40D-46BE-A246-8D45EB52B473Q38664787-5D29944E-ECF3-4DFA-9F04-AD805A64D71CQ38669131-EF91E04D-335E-4DB5-B054-48165646FA7AQ39018438-D5B08BFE-034F-4568-A229-161E2DF31F28Q39381251-6607B2ED-6606-4655-BB9F-92668CDEB052Q40974570-94B6A4AF-3153-400D-AAEB-C7CE00FB62EAQ44731136-96A3E67A-787F-4E7E-B617-471C32F7E555Q47269833-EC7A9D4F-DACC-4B1A-9B54-1FDA14A7B7C8Q48093699-B92586D6-10D9-47FE-8F34-03D99635868FQ49870129-0550C9C3-EDC2-49E6-B4D6-8C0A528E090CQ50141281-D14E8038-49B1-4B1F-829C-F639807D593FQ51075769-87FF03E0-1ED2-442F-ADE5-E86919276E81Q52639446-DA3DDB51-BB26-463D-8A5C-4BF35E387A4FQ52653323-CC745CA9-C9A8-4311-9BD9-54D74D138943Q57493686-8B8F2FB1-C1F8-4B56-A707-8E8B1CBAC5FA
P2860
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Rationally designed BCL6 inhib ...... diffuse large B cell lymphoma.
@en
type
label
Rationally designed BCL6 inhib ...... diffuse large B cell lymphoma.
@en
prefLabel
Rationally designed BCL6 inhib ...... diffuse large B cell lymphoma.
@en
P2093
P2860
P356
P1476
Rationally designed BCL6 inhib ...... diffuse large B cell lymphoma.
@en
P2093
Alexander D MacKerell
Ari M Melnick
Dongdong Liang
Erin Oswald
Fengtian Xue
Huimin Cheng
Huimin Geng
Hyo Je Cho
Joanna Cohen
John P Leonard
P2860
P304
P356
10.1172/JCI85795
P407
P577
2016-08-02T00:00:00Z